Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von GraveDigger 

Gilead Sciences Inc diskutieren

Gilead Sciences Inc

WKN: 885823 / Symbol: GILD / Name: Gilead Sciences / Aktie / Biotechnologie & medizinische Forschung / Large Cap /

60,92 €
-0,26 %

Einschätzung Sell
Rendite (%) -10,20 %
Kursziel 66,11
Veränderung
Endet am 06.09.24

Gilead Sciences, Inc. (NASDAQ: GILD) is now covered by analysts at HSBC Holdings plc. They set a "reduce" rating and a $71.00 price target on the stock.
Ratings data for GILD provided by MarketBeat

Einschätzung Buy
Rendite (%) -8,98 %
Kursziel 84,81
Veränderung
Endet am 06.09.24

Gilead Sciences, Inc. (NASDAQ: GILD) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $91.00 price target on the stock.
Ratings data for GILD provided by MarketBeat

Einschätzung Buy
Rendite (%) -10,46 %
Kursziel 88,73
Veränderung
Endet am 08.09.24

Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating. They now have a $95.00 price target on the stock, up previously from $88.00.
Ratings data for GILD provided by MarketBeat

Einschätzung Buy
Rendite (%) -9,92 %
Kursziel 97,48
Veränderung
Endet am 12.02.25

Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $115.00 to $105.00. They now have an "outperform" rating on the stock.
Ratings data for GILD provided by MarketBeat

Einschätzung Buy
Rendite (%) -7,73 %
Kursziel 83,21
Veränderung
Endet am 22.02.25

Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Mizuho from $101.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for GILD provided by MarketBeat

Einschätzung Buy
Rendite (%) -2,87 %
Kursziel 98,49
Veränderung
Endet am 20.04.25

Gilead Sciences, Inc. (NASDAQ: GILD) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $105.00 price target on the stock.
Ratings data for GILD provided by MarketBeat

Gilead Sciences, Inc. (NASDAQ: GILD) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for GILD provided by MarketBeat

Einschätzung Buy
Rendite (%) -0,72 %
Kursziel 79,45
Veränderung
Endet am 26.04.25

Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at TD Cowen from $90.00 to $85.00. They now have a "buy" rating on the stock.
Ratings data for GILD provided by MarketBeat

Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for GILD provided by MarketBeat

Einschätzung Buy
Rendite (%) 0,18 %
Kursziel 79,54
Veränderung
Endet am 01.05.25

Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Maxim Group from $90.00 to $85.00. They now have a "buy" rating on the stock.
Ratings data for GILD provided by MarketBeat